A study of Expression of Epidermal growth factor receptor (EGFR) in Lung Cancers.

Vamitha, P S (2016) A study of Expression of Epidermal growth factor receptor (EGFR) in Lung Cancers. Masters thesis, Madras Medical College, Chennai.

[img]
Preview
Text
200300116vamitha.pdf

Download (4MB) | Preview

Abstract

INTRODUCTION: Lung cancer is a highly aggressive malignancy causing high morbidity and mortality. An increasing incidence of lung cancer has been observed in India. For those with non-small cell lung cancer and patients with more advanced disease, targeted therapy has been a cornerstone of treatment. Several molecular markers in lung cancer has been introduced in the recent past. They are recent topics of interest which has emerged not only as a prognostic marker but also as markers to predict therapy response especially the EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR). The expression of this marker forms important criteria for prognosis and therapy of lung carcinomas. The aim of this study is to assess the patterns of expression of EGFR and to assess the clinical and morphological characteristics of lung carcinomas. AIMS AND OBJECTIVES: The aim of this study is to assess the expression of Epidermal Growth Factors Receptor (EGFR) in lung cancers. To compare the expression of EGFR with clinicopathological parameters in lung carcinoma. To assess the prognostic and predictive values of EGFR MATERIALS AND METHODS: Out of 412 lung specimens received during the two year study period, 178 cases were non-small cell lung carcinoma. 60 cases are randomly selected for assessing EGFR expression which includes 20 cases each of adenocarcinoma, squamous cell carcinoma and non-small cell lung carcinoma-not otherwise specified(NSCLC-NOS). RESULTS: 68.33% of the cases are positive for EGFR expression. 90.48% of the females are positive for EGFR expression96.67% of the EGFR positive cases are smokers and 40% are non smokers. Among the EGFR positive histological subtype, adenocarcinoma is the most common type with 43.90% followed by squamous cell carcinoma with 36.59% & NSCLCNOS with 19.51%. CONCLUSION: The identification of EGFR expression gives a fascinating opportunity for the development of tyrosine kinase inhibitors against non-small cell lung cancers. It is very clear from the comparison of various studies from our studies that EGFR expression is more common in females, never smokers and adenocarcinoma histological type. EGFR, being a poor prognostic factor, its expression is very important to identify the tyrosine kinase inhibitors sensitivity. Hence it is very important to find the association between EGFR expression and its clinocopathological parameters in order to select the patients for targeted therapy like erlotinib, gefitinib for advanced lung cancers. In conclusion, it is recommended that EGFR expression should be a routine test after lung resection for all non-small lung carcinoma especially adenocarcinoma and squamous cell carcinoma for better treatment for the patients.

Item Type: Thesis (Masters)
Uncontrolled Keywords: EGFR; Adenocarcinoma ; Tyrosine Kinase inhibitors ; Non-small cell lung cancers.
Subjects: MEDICAL > Pathology
Depositing User: Laksham S
Date Deposited: 10 Jul 2017 11:20
Last Modified: 13 Jun 2018 01:45
URI: http://repository-tnmgrmu.ac.in/id/eprint/1320

Actions (login required)

View Item View Item